NASD · Healthcare · Biotechnology · China
Ascentage Pharma Group International ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ascentage Pharma Group International ADR stock.
Overvalued: intrinsic value $0.24 per share, market price $14.46, margin of safety -5960.0% (as of 2026-10-30).
A 1.5x revenue multiple, discounted for its losses, values the shares at $0.24; the price of $14.46 is 5960% above that value.
131 more in this industry show a wider margin of safety.
AAPG is overvalued (as of the 2026-10-30 close). A 1.5x revenue multiple, discounted for its losses, values the shares at $0.24; the price of $14.46 is 5960% above that value.
$0.24 per share (as of the 2026-10-30 close), against a market price of $14.46. That is a margin of safety of -5960.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.